cholangitis/nikótín

Krækjan er vistuð á klemmuspjaldið

Veldu tegund tegund

Bls 1 frá 17 niðurstöður

Oral nicotine in treatment of primary sclerosing cholangitis: a pilot study.

Aðeins skráðir notendur geta þýtt greinar

Skráðu þig / skráðu þig

Currently, no accepted medical therapy for patients with primary sclerosing cholangitis (PSC) is available. Case-control studies have shown an inverse association between PSC and smoking behavior, suggesting that nicotine might have a beneficial effect in PSC. The aim of this study was to evaluate

No beneficial effects of transdermal nicotine in patients with primary sclerosing cholangitis: results of a randomized double-blind placebo-controlled cross-over study.

Aðeins skráðir notendur geta þýtt greinar

Skráðu þig / skráðu þig

OBJECTIVE Smoking is associated with a decreased risk of primary sclerosing cholangitis. We aimed to explore the therapeutic efficacy of and tolerance for transdermal nicotine treatment in this disease. METHODS Twelve patients (11 males; 37 +/- 6 years; six with ulcerative colitis) who did not

Lack of effect of transdermal nicotine on 3 cases of primary sclerosing cholangitis.

Aðeins skráðir notendur geta þýtt greinar

Skráðu þig / skráðu þig

Impact of tobacco and alcohol consumption in patients registered on waiting list on early morbidity following liver transplantation.

Aðeins skráðir notendur geta þýtt greinar

Skráðu þig / skráðu þig

BACKGROUND Liver transplantation (LT) is a high-risk surgery associated with postoperative complications. Smoking and drinking are known risk factors of long-term post-LT complications, but their role in early complications is still questioned. METHODS We retrieved from our medical files the data of

Primary sclerosing cholangitis is associated with nonsmoking: a case-control study.

Aðeins skráðir notendur geta þýtt greinar

Skráðu þig / skráðu þig

OBJECTIVE Cigarette smoking is thought to protect against the development of ulcerative colitis. The relationship between a related disease, primary sclerosing cholangitis, and smoking is unknown. The aim of this study was to determine if the relationship between smoking and sclerosing cholangitis

Characterization and clinical course of hepatobiliary carcinoma in patients with primary sclerosing cholangitis.

Aðeins skráðir notendur geta þýtt greinar

Skráðu þig / skráðu þig

OBJECTIVE Primary sclerosing cholangitis (PSC) confers a high risk of development of hepatobiliary carcinoma (HBC). The aim of the study was to identify indicators and risk factors for developing HBC in PSC patients. METHODS Thirty-nine PSC patients with HBC at time of HBC diagnosis were compared

Smoking behavior in liver transplant recipients.

Aðeins skráðir notendur geta þýtt greinar

Skráðu þig / skráðu þig

Long-term morbidity and survival after orthotopic liver transplantation (OLT) are to a large degree determined by cardiovascular disease and cancer. Tobacco use is a well-known risk factor for both. The aim of this study was to examine smoking behavior before and after OLT and to define groups at

Post-transplant malignancies in alcoholic liver disease.

Aðeins skráðir notendur geta þýtt greinar

Skráðu þig / skráðu þig

Post-transplant malignancy is emerging as an important cause of mortality in patients with cirrhosis undergoing liver transplant (LT). However, establishing the exact relationship between the two needs further evaluation. It has been observed that approximately 30% deaths after 10 years of hepatic

[Risks factors for pediatric malignant liver tumors].

Aðeins skráðir notendur geta þýtt greinar

Skráðu þig / skráðu þig

OBJECTIVE Pediatric Hepatic Malignancies (PHMs) are the result of the interaction between constitutional and environmental risk factors (RFs). We review the evidence on the main RFs associated to PHMs. METHODS Systematic review of the literature published in the last 25 years on Medline, Embase,

Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection.

Aðeins skráðir notendur geta þýtt greinar

Skráðu þig / skráðu þig

BACKGROUND Despite data suggesting a rising worldwide incidence, intrahepatic cholangiocarcinoma (IHC) remains an uncommon disease. This study analyzes changes in IHC frequency, demographics, and treatment outcome in a consecutive and single institutional cohort. METHODS Consecutive patients with

Risk factors and treatment of relapses in autoimmune pancreatitis: Rituximab is safe and effective.

Aðeins skráðir notendur geta þýtt greinar

Skráðu þig / skráðu þig

Steroid therapy is the first-line treatment for autoimmune pancreatitis but relapses are frequent. The aims were to assess the efficacy and the safety of immunomodulator treatments for relapsing autoimmune pancreatitis and rituximab in particular and to identify relapsing risk

Risk factors for cholangiocarcinoma.

Aðeins skráðir notendur geta þýtt greinar

Skráðu þig / skráðu þig

Cholangiocarcinoma occurs with a varying frequency in different areas of the world. Some of the variations in incidence rates can be explained by the distribution of risk factors in different geographic regions and ethnic groups. Several accepted risk factors for cholangiocarcinoma include

Clinical presentation, risk factors and staging systems of cholangiocarcinoma.

Aðeins skráðir notendur geta þýtt greinar

Skráðu þig / skráðu þig

Cholangiocarcinoma (CCA) is the second most common primary liver tumour. Intra-hepatic CCA develops within the liver parenchyma while extrahepatic CCA involves the biliary tree within the hepatoduodenal ligament. Hilar CCA are also called Klatskin tumour. The CCA incidence has increased worldwide

Risk factors for cholangiocarcinoma.

Aðeins skráðir notendur geta þýtt greinar

Skráðu þig / skráðu þig

Cholangiocarcinoma (CC) is the second most common primary hepatic malignancy after hepatocellular cancer. CC accounts for approximately 10%-25% of all hepatobiliary malignancies. There are considerable geographic and demographic variations in the incidence of CC. There are several established risk

Epidemiology and risk factors: intrahepatic cholangiocarcinoma.

Aðeins skráðir notendur geta þýtt greinar

Skráðu þig / skráðu þig

Intrahepatic cholangiocarcinoma (ICC) is a rare entity with a distinct clinical course and epidemiology from hilar and extrahepatic cholangiocarcinoma. ICC makes up 8-10% of cholangiocarcinomas and 10-20% of all primary liver tumors. There remains a considerable amount of geographic variation in the

Fyrri
1
2
Næst

Skráðu þig á
facebook síðu okkar

Herbal & Natural Medicine

Heillasta gagnagrunnur lækningajurtanna sem studdur er af vísindum

Virkar á 55 tungumálum
Jurtalækningar studdir af vísindum
Jurtaviðurkenning eftir ímynd
Gagnvirkt GPS kort - merktu jurtir á staðsetningu (kemur fljótlega)
Lestu vísindarit sem tengjast leit þinni
Leitaðu að lækningajurtum eftir áhrifum þeirra
Skipuleggðu áhugamál þitt og vertu vakandi með fréttarannsóknum, klínískum rannsóknum og einkaleyfum

Sláðu inn einkenni eða sjúkdóm og lestu um jurtir sem gætu hjálpað, sláðu jurt og sjáðu sjúkdóma og einkenni sem hún er notuð við.
* Allar upplýsingar eru byggðar á birtum vísindarannsóknum